Market Overview

Credit Suisse Downgrades AbbVie On Humira Competitive Concerns

Share:
Credit Suisse Downgrades AbbVie On Humira Competitive Concerns

AbbVie Inc (NYSE: ABBV)'s stock is up 51 percent year-over-year, but its lifeblood may be draining.

The Rating

Credit Suisse analysts Vamil Divan and Michael Morabito downgraded AbbVie to Underperform and lowered their price target from $104 to $89.

The Thesis

The analysts attribute AbbVie’s run to Humira legal settlements and tax reform coupled with high pipeline expectations.

“The first two points have played out but we see pipeline enthusiasm now being stretched, at best limiting room for further upside over the next 12 months,” Divan and Morabito wrote in a note.

They identify long-term fundamental concerns, particularly with emerging competition limiting Humira’s longevity.

The fourth-quarter entry of biosimilars in Europe is seen to catalyze “rapid erosion” of Humira sales, while U.S. earnings are to be stunted by impending biosimilar competition, decreased ability for AbbVie to increase prices, the impact of copay accumulator programs, and action to work around “rebate traps” ahead of rival emergence.

Price Action

AbbVie had popped 3.3 percent Wednesday to $102.92 on unrelated financing news.

Related Links:

Pharma M&A Picks Up Momentum

Novartis Gets Approval For Remicade Biosimilar In Europe

Latest Ratings for ABBV

DateFirmActionFromTo
Aug 2019UpgradesNeutralOverweight
Jun 2019UpgradesMarket PerformOutperform
May 2019Initiates Coverage OnNeutral

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Credit Suisse Michael Morabito Vamil DivanAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (ABBV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
WUBADowngrades
DLTRUpgrades
ARCCDowngrades
GTYHInitiates Coverage On7.0
NKEMaintains100.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Tesla Fixes Model 3 Brakes To Secure Consumer Reports Recommendation

30 Stocks Moving In Wednesday's Mid-Day Session